AScalate: Treat-to-target in Axial Spondyloarthritis
NCT03906136
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
304
Enrollment
INDUSTRY
Sponsor class
Conditions
Axial Spondyloarthritis
Interventions
BIOLOGICAL:
Secukinumab/Adalimumab-Biosimilar
OTHER:
Standard-of-care
Sponsor
Novartis Pharmaceuticals